The next wave of musculoskeletal regenerative therapies won’t be decided by who has the most elegant science, but by who can prove impact most convincingly. Biomarkers are the connective tissue between mechanism, regulatory approval, and market adoption. For more info : https://www.linkedin.com/in/denis-k-medaffairs/

Healthcare systems face a growing economic crisis: more than 13 million patients suffer from chronic wounds each year, yet traditional health-economic models capture only a fraction of the true burden.
https://www.linkedin.com/in/denis-k-medaffairs/

Real-world evidence (RWE) has emerged as an essential complement to clinical trials, offering continuous insights into implant durability, safety, effectiveness, and economic value across actual care settings.
https://www.linkedin.com/in/denis-k-medaffairs/

In an era where regulatory expectations, technological complexity, and global harmonization are accelerating, cross-functional excellence determines whether a device reaches patients on time and with the safety and performance they deserve.
https://www.linkedin.com/in/denis-k-medaffairs/